April 17th, 2018 by aveciapharma
HEADLINE Cell-Based Assays in a CGMP Environment: Approaches for Clinical and Commercial Stability Studies, New Webinar Hosted by Xtalks. SUB-HEADLINE Presentation to highlight the approaches used in developing consistent cell-based potency assays...
Posted in: Press Release
February 1st, 2018 by aveciapharma
CAMBRIDGE, MA – Nitto Denko Avecia, Inc. (Avecia), a leader in oligonucleotide API (active pharmaceutical ingredient) manufacturing, announced today the opening of a new corporate office in Cambridge, MA, to support its operations and corporate...
Posted in: Company News, Press Release
January 15th, 2018 by aveciapharma
NITTO AVECIA PHARMA SERVICES APPOINTS RAYMOND KACZMAREK AS PRESIDENT IRVINE, CA – Nitto Avecia Pharma Services, Inc. (Avecia Pharma), a leading CGMP contract development and manufacturing organization (CDMO), announced today that it has appointed...
Posted in: Company News, Press Release
November 7th, 2017 by aveciapharma
MILFORD, MA – Nitto Avecia, Inc. (Avecia) announced today the successful completion of the first synthesis runs at the 1.6 Mol scale which is believed to be the largest synthesis scale ever executed for oligonucleotide API (active pharmaceutical ingredients)...
Posted in: Press Release
November 14th, 2016 by aveciapharma
MILFORD, MA – Nitto Avecia Inc. (Avecia) today released its progress in expanding the company’s analytical development and oligonucleotide manufacturing capacities. The announcement signals the continuation of Avecia’s robust growth strategy...
Posted in: Press Release
October 11th, 2016 by aveciapharma
MILFORD, MA – Nitto Denko Avecia, Inc. (Avecia), today announced it has entered into a definitive agreement to acquire the assets of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio), both located in Irvine, CA....
Posted in: Company News, Press Release